Cargando…

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

INTRODUCTION: BAY 94‐9027 is an extended‒half‐life, site‐specifically PEGylated, B‐domain‒deleted recombinant factor VIII (FVIII). The PROTECT VIII main study demonstrated efficacy of bleed control using extended‐interval prophylaxis with BAY 94‐9027 for 36 weeks. AIM: To report long‐term efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lalezari, Shadan, Reding, Mark T., Pabinger, Ingrid, Holme, Pal Andre, Negrier, Claude, Chalasani, Pavani, Shin, Ho‐Jin, Wang, Maria, Tseneklidou‐Stoeter, Despina, Maas Enriquez, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900134/ https://www.ncbi.nlm.nih.gov/pubmed/31621991 http://dx.doi.org/10.1111/hae.13853

Ejemplares similares

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study
por: Reding, Mark T., et al.
Publicado: (2021)

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
por: Reding, Mark T., et al.
Publicado: (2020)

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis
por: Lalezari, Shadan, et al.
Publicado: (2020)

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
por: Reding, Mark T., et al.
Publicado: (2023)

Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
por: Kavakli, K, et al.
Publicado: (2015)

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
por: Coyle, T E, et al.
Publicado: (2014)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years
por: Mahlangu, Johnny, et al.
Publicado: (2020)

Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII)
por: Wells, Jane R., et al.
Publicado: (2019)

Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
por: Batt, Katharine, et al.
Publicado: (2019)

Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach
por: Solms, Alexander, et al.
Publicado: (2019)

Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial
por: Yang, Renchi, et al.
Publicado: (2019)

Nonclinical Safety Assessment of a Long-Acting Recombinant PEGylated Factor Eight (BAY 94-9027) With a 60 kDa PEG
por: Ivens, Inge A., et al.
Publicado: (2019)

Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison
por: Hakimi, Zalmai, et al.
Publicado: (2020)

BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial
por: Ljung, Rolf, et al.
Publicado: (2023)

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
por: Solms, Alexander, et al.
Publicado: (2020)

Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies
por: Humphries, Thomas J., et al.
Publicado: (2015)

Proteomic analysis of ceftazidime and meropenem-exposed Pseudomonas aeruginosa ATCC 9027
por: Ngo, Hong Loan, et al.
Publicado: (2023)

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
por: Pocoski, Jennifer, et al.
Publicado: (2016)

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults
por: Konkle, Barbara A., et al.
Publicado: (2023)

Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)
por: Curry, Nicola, et al.
Publicado: (2019)

Draft Genome Sequence of Pseudomonas aeruginosa ATCC 9027, Originally Isolated from an Outer Ear Infection
por: Jayal, Ambikesh, et al.
Publicado: (2017)

Perioperative, Functional, and Oncologic Outcomes of On-Clamp Versus Off-Clamp Partial Nephrectomy: An Updated Meta-analysis of 9027 Patients
por: Serag, Hosam, et al.
Publicado: (2023)

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2019)

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Draft Genome Sequence of Pseudomonas aeruginosa ATCC 9027 (DSM 1128), an Important Rhamnolipid Surfactant Producer and Sterility Testing Strain
por: Mai-Prochnow, Anne, et al.
Publicado: (2015)

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
por: Kenet, Gili, et al.
Publicado: (2021)

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
por: Lalezari, S, et al.
Publicado: (2014)

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
por: Skinner, Mark W., et al.
Publicado: (2021)

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A
por: Di Minno, Giovanni, et al.
Publicado: (2019)

Symphony No. 94 Surprise Symphony No. 94 Miracle/
por: Haydn, Joseph

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
por: Sun, Jing, et al.
Publicado: (2021)

Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis
por: Pabinger, Ingrid, et al.
Publicado: (2017)

www 94
Publicado: (2017)

Hadron '94
por: Collective
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_l4g108hmqf3r5eunpm93vs3i44